FKBP9

Across TCGA pan-cancer cohorts, FKBP9 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FKBP9 data layer compared with 26 for mass-spec protein and 8 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher FKBP9 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FKBP9 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SKCM, KICH, and PCPG are the cancer types where FKBP9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	All	0.255	0.784	<.001	24	view →
KICH	OS	Median	All	0.155	0.926	<.001	21	view →
PCPG	OS	Median	All	0.010	0.946	<.001	12	view →
BLCA	OS	Median	All	0.099	0.447	.008	12	view →
UCEC	DFS	Median	All	1.000	0.625	.007	12	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FKBP9–SKCM (OS)

Open the SKCM breakdown →